Wandstrat T L
School of Pharmacy, Robert C Byrd Health Sciences Center, West Virginia University/Charleston Division 25304, USA.
Ann Pharmacother. 1997 Jan;31(1):83-8. doi: 10.1177/106002809703100114.
To review the clinical data detailing the use of respiratory syncytial virus immune globulin intravenous (RSV-IGIV) in infants and children. DATA SOURCES; A MEDLINE search (1990-1996) was used to identify all publications that dealt with RSV-IGIV clinical trials, pharmacology, and pharmacokinetics in infants and children. Bibliographies of articles were also used.
All abstracts and clinical trials were reviewed.
Study design, population, efficacy, and safety data were retained.
RSV-IGIV is an immunoglobulin product with serum neutralizing titers against RSV. It has been shown to reduce hospital stay, admissions, intensive care unit admissions, and mechanical ventilation days in infants and children with RSV pneumonia or bronchiolitis who are younger than 24 months of age and were born prematurely, or have bronchopulmonary dysplasia. RSV-IGIV is well tolerated by infants and children.
RSV-IGIV is an effective prophylactic agent against serious RSV disease in select groups of infants and children.
回顾详细介绍呼吸道合胞病毒免疫球蛋白静脉注射剂（RSV-IGIV）在婴幼儿中使用情况的临床数据。资料来源：使用MEDLINE检索（1990 - 1996年）来识别所有涉及RSV-IGIV在婴幼儿中的临床试验、药理学和药代动力学的出版物。还查阅了文章的参考文献。
对所有摘要和临床试验进行了审查。
保留了研究设计、研究对象、疗效和安全性数据。
RSV-IGIV是一种对呼吸道合胞病毒具有血清中和效价的免疫球蛋白产品。已证明它可减少24个月以下、早产或患有支气管肺发育不良的患呼吸道合胞病毒肺炎或细支气管炎的婴幼儿的住院时间、住院次数、重症监护病房入住率和机械通气天数。婴幼儿对RSV-IGIV耐受性良好。
RSV-IGIV是特定组别的婴幼儿预防严重呼吸道合胞病毒疾病的有效预防剂。
